Soleil Boughton Sells 2,637 Shares of Hims & Hers Health (NYSE:HIMS) Stock

Key Points

• Insider Soleil Boughton sold 2,637 shares of Hims & Hers Health stock for approximately $133,168.50, decreasing their ownership by 1.56% to 166,404 shares.
• Hims & Hers Health's stock is currently trading at $57.74, showing a 2.7% increase in midday trading with a market cap of $13.05 billion.
• The company reported $544.83 million in revenue for the latest quarter, marking a 72.6% increase year-over-year but missing consensus estimates by $5.23 million.

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) insider Soleil Boughton sold 2,637 shares of the stock in a transaction dated Wednesday, September 17th. The stock was sold at an average price of $50.50, for a total transaction of $133,168.50. Following the transaction, the insider owned 166,404 shares of the company's stock, valued at $8,403,402. This represents a 1.56% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Soleil Boughton also recently made the following trade(s):

• On Monday, August 25th, Soleil Boughton sold 2,571 shares of Hims & Hers Health stock. The stock was sold at an average price of $44.53, for a total value of $114,486.63.
• On Monday, August 11th, Soleil Boughton sold 2,572 shares of Hims & Hers Health stock. The stock was sold at an average price of $51.64, for a total value of $132,818.08.
• On Monday, July 28th, Soleil Boughton sold 2,572 shares of Hims & Hers Health stock. The stock was sold at an average price of $58.70, for a total transaction of $150,976.40.
• On Monday, July 14th, Soleil Boughton sold 2,572 shares of Hims & Hers Health stock. The shares were sold at an average price of $47.82, for a total value of $122,993.04.
• On Monday, June 30th, Soleil Boughton sold 2,572 shares of Hims & Hers Health stock. The shares were sold at an average price of $50.50, for a total transaction of $129,886.00.

Hims & Hers Health Stock Down 0.1%

HIMS stock traded down $0.05 during midday trading on Monday, hitting $57.77. The company's stock had a trading volume of 18,693,929 shares, compared to its average volume of 27,452,044. The company has a current ratio of 4.98, a quick ratio of 4.46 and a debt-to-equity ratio of 1.72. Hims & Hers Health, Inc. has a 12 month low of $16.05 and a 12 month high of $72.98. The company has a market cap of $13.06 billion, a PE ratio of 72.21, a P/E/G ratio of 3.91 and a beta of 2.14. The firm's 50-day moving average is $50.83 and its 200-day moving average is $45.92.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its earnings results on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.01). The business had revenue of $544.83 million for the quarter, compared to the consensus estimate of $550.06 million. Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The business's quarterly revenue was up 72.6% compared to the same quarter last year. During the same quarter last year, the firm posted $0.06 earnings per share. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, equities research analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Morgan Stanley reissued an "equal weight" rating and issued a $40.00 price objective on shares of Hims & Hers Health in a research note on Wednesday, June 11th. Canaccord Genuity Group reissued a "buy" rating and issued a $68.00 price target on shares of Hims & Hers Health in a research report on Friday, September 12th. Citigroup reiterated a "sell" rating on shares of Hims & Hers Health in a research note on Monday, June 23rd. UBS Group set a $30.00 price target on Hims & Hers Health in a research report on Monday, June 23rd. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Hims & Hers Health in a research note on Tuesday, August 5th. Two investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of "Reduce" and a consensus price target of $38.92.

Institutional Trading of Hims & Hers Health

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Smartleaf Asset Management LLC increased its stake in Hims & Hers Health by 15.7% in the first quarter. Smartleaf Asset Management LLC now owns 1,672 shares of the company's stock valued at $49,000 after purchasing an additional 227 shares during the period. Bessemer Group Inc. raised its holdings in Hims & Hers Health by 105.8% during the second quarter. Bessemer Group Inc. now owns 607 shares of the company's stock worth $30,000 after purchasing an additional 312 shares during the last quarter. True Vision MN LLC increased its holdings in Hims & Hers Health by 3.6% during the 2nd quarter. True Vision MN LLC now owns 9,376 shares of the company's stock valued at $467,000 after acquiring an additional 328 shares in the last quarter. Allworth Financial LP raised its position in shares of Hims & Hers Health by 20.0% during the 1st quarter. Allworth Financial LP now owns 2,006 shares of the company's stock worth $56,000 after purchasing an additional 334 shares during the last quarter. Finally, Signaturefd LLC lifted its position in shares of Hims & Hers Health by 17.7% in the first quarter. Signaturefd LLC now owns 2,586 shares of the company's stock valued at $76,000 after acquiring an additional 388 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company's stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.